Melior Discovery Inc.
http://www.meliordiscovery.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Melior Discovery Inc.
On The Move: Who’s Going Where In Biopharma And Medtech Start-Ups
Recent executive-level hires and director appointments at venture capital firms and biopharma and medtech start-ups.
The Value of Drug Repositioning: Longer Patent Life
According to Gene Logic, there's value in failed Phase II candidates-so long as safety's not the problem. The company claims that repositioning a compound in a new indication creates an asset worth 27% more, in net present value terms, than an equivalent in-licensed drug.
A New Approach to Repurposing: Ditch the Hypotheses
By pulling together 35 publicly available gold-standard animal models, Melior Discovery has built a stable of what it calls privileged compounds. The repurposing company augments its VC funds with service deals and is aiming to progress its lead compound into Phase I studies in 2007.
Selected Start-Ups (5/06)
In Vivo briefly summarizes the technologies of these recently founded companies: Carbylan BioSurgery, KAHR Pharmaceuticals, Melior Discovery, Myomo, Nanonucleant, Pelican Life Sciences.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice